Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Ratifies Free Trade Agreement With U.S., Pleasing Pharma Industry

This article was originally published in PharmAsia News

Executive Summary

Patent linkage provisions among key benefits for the pharmaceutical industry.

You may also be interested in...



Korean And U.S. Presidents Welcome Long-Awaited Korea-U.S. FTA Ratification; Now Eyes on Seoul

SEOUL -Korean President Lee Myung-bak and U.S. President Barack Obama both welcomed and celebrated the U.S. Congress's ratification of the Free Trade Agreement, saying the historic free trade deal will benefit both countries. But ratification is still needed in South Korea, and political maneuvering by the country's ruling and opposition parties may delay the process

Pharma Industry Applauds Final Push For Ratification Of Korea-U.S. FTA, Patent Linkage, Transparency, Among Benefits

SEOUL - South Korean Prime Minister Kim Hwang-sik called on cabinet ministers to ratify Korea's free trade agreement with the United States during the country's National Assembly session Oct. 4

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC076780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel